Lipocine Reports $9.6M 2025 Loss, $14.9M Cash, April LPCN 1154 Data
Lipocine reported a net loss of $9.6 million ($1.69 per share) on $2.0 million revenue for 2025, versus $11.2 million in 2024, ending the year with $14.9 million in cash and investments. The firm completed its Phase 3 postpartum depression candidate LPCN 1154 study in February and expects top-line results in April.
1. Financial Performance
Lipocine recorded a net loss of $9.6 million ($1.69 per share) for 2025, compared with net income of $8,352 in 2024. Revenue declined to $2.0 million from $11.2 million, driven by $1.5 million in license revenue and $480,000 in TLANDO royalties, while R&D expenses rose to $8.6 million and G&A fell to $3.8 million.
2. Cash Position and Runway
The company ended 2025 with $14.9 million in unrestricted cash, equivalents and marketable securities, down from $21.6 million at the end of 2024. This cash position reflects increased clinical study spending and positions Lipocine to fund ongoing Phase 3 activities into mid-2026.
3. LPCN 1154 Phase 3 Progress
Lipocine completed enrollment and final patient visits for its LPCN 1154 Phase 3 postpartum depression trial in February 2026. Top-line safety and efficacy data are expected in early April, paving the way for a 505(b)(2) NDA submission in mid-2026.
4. Other Pipeline Candidates and Partnerships
Beyond LPCN 1154, Lipocine is advancing LPCN 2201 for major depressive disorder and plans a Phase 2 proof-of-concept study for LPCN 2101 in epilepsy. The company is exploring a Phase 2 trial for obesity candidate LPCN 2401 and continues expanding TLANDO licensing and distribution deals across North America, South Korea, the GCC and Brazil.